Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Plasma Cell × Heparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Venous Thrombosis 2 Thromboembolism 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Immunoblastic Lymphadenopathy 2 Hodgkin Disease 2 Burkitt Lymphoma 2 Wilms Tumor 1 Waldenstrom Macroglobulinemia 1 Venous Thromboembolism 1 Thrombosis 1 Testicular Neoplasms 1 Spinal Stenosis 1 Sezary Syndrome 1 Sarcoma 1 Resected Liver Metastases From Colorectal Cancer 1 Recurrence 1 Pulmonary Embolism 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

Dexamethasone 101 Cyclophosphamide 91 Melphalan 85 Bortezomib 64 Peripheral Blood Stem Cell Transplantation 56 Lenalidomide 51 fludarabine phosphate 46 Busulfan 46 Filgrastim 45 Radiotherapy 34 Antilymphocyte Serum 33 Thalidomide 32 Tacrolimus 31 Mycophenolic Acid 27 fludarabine 23 Cyclosporine 23 Methotrexate 21 Etoposide 21 Calcium Dobesilate 21 Prednisone 20 Whole-Body Irradiation 19 Methylprednisolone 18 pomalidomide 16 carfilzomib 16 Granulocyte Colony-Stimulating Factor 15 sargramostim 14 daratumumab 14 Cord Blood Stem Cell Transplantation 13 Carmustine 13 Rituximab 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡